Patents by Inventor Pachamuthu Kandasamy
Pachamuthu Kandasamy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11944687Abstract: This disclosure relates to an improved process for the preparation of carbohydrate conjugates. The disclosure also relates to carbohydrate conjugated iRNA agents comprising these carbohydrate conjugates, which have improved purity and are advantageous for the in vivo delivery of the iRNA agents.Type: GrantFiled: July 5, 2022Date of Patent: April 2, 2024Assignee: ALNYLAM PHARMACEUTICALS, INC.Inventors: Jayaprakash K. Nair, Alexander V Kel'in, Pachamuthu Kandasamy, Kallanthottathil G Rajeev, Muthiah Manoharan
-
Publication number: 20240026358Abstract: Among other things, the present disclosure provides oligonucleotides and compositions thereof. In some embodiments, provided oligonucleotides and compositions are useful for adenosine modification. In some embodiments, the present disclosure provides methods for treating various conditions, disorders or diseases that can benefit from adenosine modification.Type: ApplicationFiled: March 11, 2022Publication date: January 25, 2024Inventors: Prashant Monian, Chikdu Shakti Shivalila, Subramanian Marappan, Chandra Vargeese, Pachamuthu Kandasamy, Genliang Lu, Hui Yu, David Charles Donnell Butler, Luciano Henrique Apponi, Mamoru Shimizu, Stephany Michelle Standley, David John Boulay, Andrew Guzior Hoss, Jigar Desai, Jack David Godfrey, Hailin Yang, Naoki Iwamoto, Jayakanthan Kumarasamy, Anthony Lamattina, Tom Liantang Pu
-
Patent number: 11873316Abstract: The present disclosure, among other things, provides technologies for oligonucleotide synthesis. In some embodiments, the present disclosure provides phosphoramidites and methods for synthesis thereof. In some embodiments, provided methods provides higher yields and/or purities. In some embodiments, provided methods remove byproducts without contact with an aqueous solution.Type: GrantFiled: November 22, 2017Date of Patent: January 16, 2024Assignee: WAVE LIFE SCIENCES LTD.Inventors: David Charles Donnell Butler, Pachamuthu Kandasamy, Subramanian Marappan, Ik-Hyeon Paik, Jayakanthan Kumarasamy, Gopal Reddy Bommineni
-
Publication number: 20230392137Abstract: Among other things, the present disclosure provides oligonucleotides and compositions thereof. In some embodiments, provided oligonucleotides and compositions are useful for adenosine modification. In some embodiments, the present disclosure provides methods for treating various conditions, disorders or diseases that can benefit from adenosine modification.Type: ApplicationFiled: September 26, 2022Publication date: December 7, 2023Inventors: Prashant Monian, Chikdu Shakti Shivalila, Subramanian Marappan, Chandra Vargeese, Pachamuthu Kandasamy, Genliang Lu, Hui Yu, David Charles Donnell Butler, Luciano Henrique Apponi, Mamoru Shimizu, Stephany Michelle Standley, David John Boulay, Andrew Guzior Hoss, Jigar Desai, Jack David Godfrey, Hailin Yang, Naoki Iwamoto, Jayakanthan Kumarasamy, Anthony Lamattina, Tom Liantang Pu
-
Publication number: 20230348524Abstract: Among other things, the present disclosure provides technologies for oligonucleotide preparation, particularly chirally controlled oligonucleotide preparation, which technologies provide greatly improved crude purity and yield, and significantly reduce manufacturing costs.Type: ApplicationFiled: March 17, 2023Publication date: November 2, 2023Inventors: Keith Andrew Bowman, Chandra Vargeese, David Charles Donnell Butler, Pachamuthu Kandasamy, Mohammed Rowshon Alam, Mamoru Shimizu, Stephany Michelle Standley, Vincent Aduda, Gopal Reddy Bommineni, Snehlata Tripathi, Ilia Korboukh
-
Publication number: 20230329201Abstract: Among other things, the present disclosure provides cells and non-human animals engineered to express an ADAR1 polypeptide or a characteristic portion thereof. In some embodiments, the present disclosure provides cells and non-human animals engineered to express a human ADAR1 polypeptide or a characteristic portion thereof. In some embodiments, non-human animals are genetically modified rodents such as mice, rat, etc. In some embodiments, non-human animals are mice. In some embodiments, the present disclosure provides technologies for assessing an agent comprising administering the agent to a cell or non-human animal engineered to express an ADAR1 polypeptide or a characteristic portion thereof. In some embodiments, such a cell or non-human animal is engineered to express a human ADAR1 polypeptide or a characteristic portion thereof. In some embodiments, an agent is a pharmaceutical agent. In some embodiments, an agent is or comprises an oligonucleotide.Type: ApplicationFiled: August 23, 2021Publication date: October 19, 2023Inventors: Hailin Yang, Prashant Monian, Chikdu Shakti Shivalila, Subramanian Marappan, Chandra Vargeese, Pachamuthu Kandasamy, Genliang Lu, Hui Yu, David Charles Donnell Butler, Luciano Henrique Apponi, Mamoru Shimizu, Stephany Michelle Standley, David John Boulay, Jack David Godfrey, Naoki Iwanmoto
-
Publication number: 20230295619Abstract: Among other things, the present disclosure provides oligonucleotides, compositions, and methods for preventing and/ or treating various conditions, disorders or diseases. In some embodiments, provided technologies comprise nucleobase modifications, sugar modifications, intemucleotidic linkage modifications and/or patterns thereof, and have improved properties, activities and/or selectivities. In some embodiments, provided technologies target MAPT. In some embodiments, the present disclosure provides MAPT oligonucleotides, compositions and methods for preventing and/or treating MAPT-associated conditions, disorders or diseases, such as Alzheimer’s Disease (AD) or Frontotemporal Dementia (FTD).Type: ApplicationFiled: February 26, 2021Publication date: September 21, 2023Inventors: Abbie Madeline Maguire, Priyanka Shiva Prakasha, Naoki Iwamoto, Kenneth Allan Longo, Chandra Vargeese, Kevin Kim, Elena Dale, Pachamuthu Kandasamy, Mamoru Shimizu
-
Patent number: 11739325Abstract: Among other things, the present disclosure provides oligonucleotides, compositions, and methods thereof. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., knockdown ability, stability, delivery, etc. In some embodiments, the oligonucleotides decrease the expression, activity and/or level of a C9orf72 gene, including but not limited to, one comprising a repeat expansion, or a gene product thereof.Type: GrantFiled: August 7, 2018Date of Patent: August 29, 2023Assignee: WAVE LIFE SCIENCES LTD.Inventors: Chandra Vargeese, Zhong Zhong, Naoki Iwamoto, Jason Jingxin Zhang, Jean-Cosme Dodart, Yuanjing Liu, Pachamuthu Kandasamy, Sethumadhavan Divakaramenon, Genliang Lu, Subramanian Marappan
-
Publication number: 20230256098Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.Type: ApplicationFiled: April 20, 2023Publication date: August 17, 2023Inventors: Martin MAIER, Muthusamy JAYARAMAN, Akin AKINC, Shigeo MATSUDA, Pachamuthu KANDASAMY, Kallanthottathil G. RAJEEV, Muthiah MANOHARAN
-
Patent number: 11718638Abstract: The present disclosure, among other things, provides technologies for synthesis, including reagents and methods for stereoselective synthesis. In some embodiments, the present disclosure provides compounds useful as chiral auxiliaries. In some embodiments, the present disclosure provides reagents and methods for oligonucleotide synthesis. In some embodiments, the present disclosure provides reagents and methods for chirally controlled preparation of oligonucleotides. In some embodiments, technologies of the present disclosure are particularly useful for constructing challenging internucleotidic linkages, providing high yields and stereoselectivity.Type: GrantFiled: June 21, 2018Date of Patent: August 8, 2023Assignee: WAVE LIFE SCIENCES LTD.Inventors: David Charles Donnell Butler, Christopher P. Hencken, Naoki Iwamoto, Pachamuthu Kandasamy, Alvaro Andres Lanao, Genliang Lu, Mamoru Shimizu, Sethumadhavan Divakaramenon, Chandra Vargeese, Gopal Reddy Bommineni, Subramanian Marappan
-
Publication number: 20230220384Abstract: Among other things, the present disclosure provides oligonucleotides and compositions thereof. In some embodiments, provided oligonucleotides and compositions are useful for adenosine modification. In some embodiments, the present disclosure provides methods for treating various conditions, disorders or diseases that can benefit from adenosine modification.Type: ApplicationFiled: October 6, 2020Publication date: July 13, 2023Inventors: Prashant Monian, Chikdu Shakti Shivalila, Subramanian Marappan, Chandra Vargeese, Pachamuthu Kandasamy, Genliang Lu, Hui Yu, David Charles Donnell Butler, Luciano Henrique Apponi, Mamoru Shimizu, Stephany Michelle Standley, David John Boulay, Andrew Guzior Hoss, Jigar Desai, Jack David Godfrey, Hailin Yang, Naoki Iwamoto
-
Publication number: 20230203484Abstract: The present disclosure provides double stranded oligonucleotides, compositions, and methods relating thereto. The present disclosure encompasses the recognition that structural elements of double stranded oligonucleotides, such as base sequence, chemical modifications (e.g, modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, and/or stereochemistry (e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)), and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g, RNA interference (RNAi) activity, stability, delivery, etc. The present disclosure also provides methods for treatment of diseases using provided double stranded oligonucleotide compositions, for example, in RNA interference.Type: ApplicationFiled: May 24, 2021Publication date: June 29, 2023Applicant: WAVE LIFE SCIENCES LTD.Inventors: Chandra VARGEESE, Naoki IWAMOTO, Luciano H. APPONI, David Charles Donnell BUTLER, Pachamuthu KANDASAMY, Subramanian MARAPPAN, Snehlata TRIPATHI, Wei LIU, Mugdha BEDEKAR, Vinod VATHIPADIEKAL
-
Publication number: 20230203087Abstract: The present disclosure provides modified oligonucleotides and compositions and methods thereof. In some embodiments, provided technologies comprise modified sugars and/or modified internucleotidic linkages. In some embodiments, the present disclosure provides technologies for preparing modified oligonucleotides. In some embodiments, the present disclosure provides chirally controlled oligonucleotide compositions and methods for their preparation and uses.Type: ApplicationFiled: May 24, 2021Publication date: June 29, 2023Inventors: Pachamuthu Kandasamy, Jayakanthan Kumarasamy, Chandra Vargeese, Subramanian Marappan, Gopal Reddy Bommineni, Mamoru Shimizu, Naoki Iwamoto, Stephany Michelle Standley, Yuanjing Liu, Amy Jada Andreucci, Genliang Lu, Onanong Chivatakarn, Akbar Husain Khan
-
Patent number: 11679158Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.Type: GrantFiled: December 17, 2021Date of Patent: June 20, 2023Assignee: ALNYLAM PHARMACEUTICALS, INC.Inventors: Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan
-
Patent number: 11633480Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.Type: GrantFiled: February 14, 2022Date of Patent: April 25, 2023Assignee: ALNYLAM PHARMACEUTICALS, INC.Inventors: Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan
-
Patent number: 11633479Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.Type: GrantFiled: February 14, 2022Date of Patent: April 25, 2023Assignee: ALNYLAM PHARMACEUTICALS, INC.Inventors: Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan
-
Patent number: 11612657Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.Type: GrantFiled: February 14, 2022Date of Patent: March 28, 2023Assignee: ALNYLAM PHARMACEUTICALS, INC.Inventors: Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan
-
Publication number: 20230089442Abstract: Among other things, the present disclosure provides technologies for oligonucleotide preparation, particularly chirally controlled oligonucleotide preparation, which technologies provide greatly improved crude purity and yield, and significantly reduce manufacturing costs.Type: ApplicationFiled: March 19, 2020Publication date: March 23, 2023Inventors: Pachamuthu Kandasamy, Mamoru Shimizu, David Charles Donnell Butler, Jayakanthan Kumarasamy, Gopal Reddy Bommineni, Mohammed Rowshon Alam, Sethumadhavan Divakaramenon, Bijay Tilak Bhattarai, Chandra Vargeese, Keith Andrew Bowman, Stephany Michelle Standley
-
Patent number: 11608355Abstract: Among other things, the present disclosure provides technologies for oligonucleotide preparation, particularly chirally controlled oligonucleotide preparation, which technologies provide greatly improved crude purity and yield, and significantly reduce manufacturing costs.Type: GrantFiled: September 17, 2018Date of Patent: March 21, 2023Assignee: WAVE LIFE SCIENCES LTD.Inventors: Keith Andrew Bowman, Chandra Vargeese, David Charles Donnell Butler, Pachamuthu Kandasamy, Mohammed Rowshon Alam, Mamoru Shimizu, Stephany Michelle Standley, Vincent Aduda, Gopal Reddy Bommineni, Snehlata Tripathi, Ilia Korboukh
-
Patent number: 11590229Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.Type: GrantFiled: February 14, 2022Date of Patent: February 28, 2023Assignee: ALNYLAM PHARMACEUTICALS, INC.Inventors: Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan